This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Advancing Diagnosis and Management of Atopic Dermatitis in Children and Adolescents

Advancing Diagnosis and Management of Atopic Dermatitis in Children and Adolescents



Time to Complete

1.25 hours


February 20, 2019


February 20, 2020
Add to Queue

Maximum Credits

1.25 / AMA PRA Category 1 CreditTM

Accredited Provider

Provided by Integrity Continuing Education

Commercial Supporter

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

Program Description

Atopic dermatitis (AD) and its associated comorbidities represent a significant healthcare burden due in large part to gaps in care and unmet medical needs pertaining to its diagnosis, assessment and treatment.

Difficulties associated with physician-patient-caregiver interaction that impacts patient adherence are common. Clinicians frequently assume that the information given during an office visit will be carried out appropriately. However, the use of a shared decision-making model has been stressed by the US Institute of Medicine in the clinical setting. The identified limitations of physician communication with patients and caregivers, combined with the fact that families do not routinely feel comfortable with the management of their children’s skin disease highlights a critical gap in care of children and adolescents with AD.

Improving clinician-patient-caregiver communication is critical to ensure improved outcomes in AD. This program will provide strategies to engage patients in their care, including the use of a written action plan for AD. It will also review updated guidelines, recommendations, and recent clinical evidence to inform treatment decisions to alleviate symptom burden of AD and its severity.

Intended Audience

This educational initiative has been designed for pediatricians, family physicians, nurse practitioners, and physician assistants involved in the management of children and adolescents with AD.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Review updated guidelines to accurately diagnose AD and make treatment decisions based on severity for children and adolescents
  • Evaluate recent clinical evidence on the utility of approved and emerging biologic agents that treat moderate-to-severe AD
  • Describe effectiveness of shared decision making in pediatric conditions and using action plan components for managing AD

Conflict Of Interest Disclosure Policy

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education is committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.

The faculty/planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity.


Peter A. Lio, MD
Clinical Assistant Professor
Dermatology and Pediatrics
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Dr. Lio discloses the following:
Consulting Fees: AbbVie, Eli Lilly, Exeltis, Galderma, gPower, Heel, IntraDerm, Johnson & Johnson, Kiniksa, L’Oreal/La Roche Posay, Pfizer, Pierre-Fabre, Realm, Sanofi Genzyme and Regeneron Pharmaceuticals, Theraplex, UCB, Unilever, Valeant Pharmaceuticals, LLC
Speakers’ Bureaus: Galderma, La Roche Posay, Pfizer, Sanofi Genzyme and Regeneron Pharmaceuticals
Contracted Research: AOBiome, Sanofi Genzyme and Regeneron Pharmaceuticals
Ownership Interests: Altus Labs/Franklin Biosci, DermVeda, Syncere Skin Systems, Theraplex

Elaine C. Siegfried, MD
Professor of Pediatrics and Dermatology
Director, Division of Pediatric Dermatology
Saint Louis University
Cardinal Glennon Children’s Hospital
St. Louis, Missouri

Dr. Siegfried discloses the following:
Fees for Non-CME/CE Services: Pfizer, Regeneron
Contracted Research: Eli Lilly, Regeneron, Verrica Pharmaceuticals
Ownership Interests: Janssen & DSMD: Pfizer, Noven Pharmaceuticals, Inc.

Accredited Provider Disclosure

The following planner and manager, Michelle R. Rizzo, ELS, hereby states that she or her spouse/ life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education and Sanofi Genzyme and Regeneron Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


There are no fees for participating and receiving CME credit for this activity. During the period of February 20, 2019 through February 20, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form
A certificate will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or higher. Please proceed with the activity until you have successfully passed the post-test, completed the evaluation and received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc., at (855) 835-4004 or

If you have any questions relating to your certificate or other issues with this activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue